Stay up-to-date with NeOnc's latest developments. Explore our latest news, official press releases, and in-depth research articles to follow our journey of innovation and stay informed about our progress and contributions to the field.
LATEST FROM NEONC
Our Latest Research & Study
Latest Studies
NEO100 Research Shows Impact On Recurrent Grade 4 Astrocytoma
Patients with grade 4 gliomas, particularly those experiencing recurrence, need better treatment options. Researchers are developing NEO100, a clinical-grade version of perillyl alcohol, a natural compound, to be delivered intranasally…
NEO100 Intranasal Delivery Technology Shows Promise for Better Therapeutic Results.
This paper discusses the need for better treatment options for patients suffering from astrocytoma and glioblastoma (GBM), the two most frequently diagnosed primary brain tumors. In addition, secondary brain cancers…
Study Shows NEO400 Has Therapeutic Effect On UV-Induced Skin Damage
A study conducted by NeOnc Technologies Holdings and published in the Wiley Online Research Library examined the effects of NeOnc’s NEO400 formulation for treating skin damage caused by prolonged ultraviolet…
NEO100 Enhances Entry And Therapeutic Activity Of Chimeric Antigen Receptor T Cells
In an article published in the Journal of Neurosurgery website, the study results were posted on Neonc Technologies Holdings’ recent animal study looking at the efficacy of using the NEO100…
Transfemoral Injection of NEO100 Provides Potential for Delivery of Therapeutics to the Brain
In an article published on the Oncotarget.com website, the use of transfemoral injection of NEO100 to provide entry for therapeutics into the brain is explored. The paper provides an overview…
Postsurgical Biopsy Shows Viability of NEO100 Intranasal Delivery
In a recent case trial follow up of a patient with a recurring glioblastoma (GBM) tumor who had been undergoing NEO100 intranasal treatment, a postsurgical biopsy of the tumor showed…
Latest Videos
Videos
Latest Press Releases
FROM THE PRESS ROOM
NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to its Board of Directors
Appointment deepens the Board’s strategic and financial oversight as the Company advances its NEO platform toward its next phase of growth CALABASAS, Calif., July 27, 2026 (GLOBE NEWSWIRE) — NeOnc…
NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition
FDA feedback provides detailed manufacturing and formulation requirements for continued late-stage development of NEO212 CALABASAS, Calif., July 15, 2026 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) (“NeOnc” or…
NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone
Authorization covers all three NEO100 programs across adult Phase 1 through Phase 2, plus pediatric studies Extends NeOnc’s UAE footprint beyond NEO212 and complements ongoing U.S. development, where NEO100 holds…
NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development
Clearance enables Phase 2 evaluation of NEO212, the Company’s oral perillyl alcohol-temozolomide conjugate, in the United Arab Emirates Follows completion of Phase 1 dose escalation and selection of 610 mg…
NeOnc Provides Business Update and Reports Q1 2026 Financial Results
CALABASAS, Calif., May 18, 2026 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company advancing two Phase 2 programs in central nervous…
NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts
CALABASAS, Calif., May 05, 2026 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing innovative therapies for central nervous…
Latest News & Insights
FROM THE NEWS ROOM
Top Entrepreneurs Going into 2026
Publication Date: February 23, 2026 Published By: USA Today Article Link: https://www.usatoday.com/story/special/contributor-content/2026/02/23/top-entrepreneurs-going-into-2026/88825698007/ Entrepreneurship heading into 2026 looks very different from what it did even a few years ago. A look…
NeOnc Technologies: From Survival Mode To Expansion Mode
Summary NeOnc Technologies Holdings is a micro-cap biotech focused on innovative brain cancer treatments, NEO100 and NEO212, both in early clinical trials. NTHI’s financials are challenging, with no revenue, rising…
Building Biotech Excellence: The Growth Strategy Behind NeOnc Technologies’ Vision
Publication Date: March 13, 2025Published By: Venture BeatArticle Link: https://venturebeat.com/business/building-biotech-excellence-the-growth-strategy-behind-neonc-technologies-vision/ In his years as Director of Surgical Neuro-Oncology at the University of Southern California (USC), Dr. Thomas Chen has witnessed…
USC-licensed Startup NeOnc Technologies Celebrates NASDAQ Listing
Publication Date: March 27, 2025Published By: Healthcare ExecutiveArticle Link: https://www.healthcareexecutive.in/blog/usc-licensed-startup On Wednesday, a USC-licensed startup biomedical company and Keck Medicine of USC neurosurgeon focused on treating brain cancer are taking…
NASDAQ’S Opening Bell Will Ring For USC Research Startup
Publication Date: March 25, 2025 Published By: USC Today Article Link: https://today.usc.edu/nasdaqs-opening-bell-will-ring-for-usc-research-startup/ A USC-licensed startup biomedical company and a Keck Medicine of USC neurosurgeon focused on treating brain cancer are…
Pioneering a New Era in Brain Cancer Treatment with NASDAQ Listing
Publication Date: March 25, 2025 Published By: USC Today Article Link: https://healthcare360magazine.com/nasdaq-visionaries-neonc-technologies/ The landscape of healthcare is in a state of perpetual evolution, driven by relentless innovation and a desire…